Myocardial viability in patients with ischemic cardiomyopathy - Evaluation by 3-D integration of myocardial scintigraphic data - And coronary angiographic data

Thomas H. Schindler, Egbert U. Nitzsche, Nobuhisa Magosaki, Michael Mix, Alvaro D. Facta, John O. Prior, Ulrich Solzbach, Heinrich R. Schelbert, Hanjoerg Just

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the prevalence of viable myocardium in patients with ischemic cardiomyopathy and, to evaluate the value of three-dimensional (3-D) fusion imaging of myocardial scintigraphic and angiographic data to assign coronary artery lesions to the corresponding viable and nonviable myocardial territory. Procedures: In 105 patients, the combination of perfusion and metabolic imaging with 201thallium (201TI) single-photon emission computed tomography (SPECT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) determined viability in dysfunctional myocardium. In addition, the value of 3-D scintigraphic fusion imaging was assessed in these patients. Results: Based on the presence of viable dysfunctional myocardium, 54% of patients with ischemic cardiomyopathy may be considered for coronary revascularization. In 31 of 105 patients, the 3-D fusion imaging was estimated to be helpful in the diagnostic and interpretative process. Conclusion: In patients with end-stage coronary artery disease scintigraphic imaging is most important in the decision-making process. Three-dimensional fusion imaging may add important information in approximately 30% of these patients.

Original languageEnglish (US)
Pages (from-to)160-171
Number of pages12
JournalMolecular Imaging and Biology
Volume6
Issue number3
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Cardiomyopathies
Three-Dimensional Imaging
Myocardium
Perfusion Imaging
Fluorodeoxyglucose F18
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Coronary Artery Disease
Coronary Vessels
Decision Making

Keywords

  • 3-D fusion imaging
  • Angiography
  • Cardiomyopathy
  • Coronary disease
  • Tomography
  • Viability

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

Myocardial viability in patients with ischemic cardiomyopathy - Evaluation by 3-D integration of myocardial scintigraphic data - And coronary angiographic data. / Schindler, Thomas H.; Nitzsche, Egbert U.; Magosaki, Nobuhisa; Mix, Michael; Facta, Alvaro D.; Prior, John O.; Solzbach, Ulrich; Schelbert, Heinrich R.; Just, Hanjoerg.

In: Molecular Imaging and Biology, Vol. 6, No. 3, 05.2004, p. 160-171.

Research output: Contribution to journalArticle

Schindler, Thomas H. ; Nitzsche, Egbert U. ; Magosaki, Nobuhisa ; Mix, Michael ; Facta, Alvaro D. ; Prior, John O. ; Solzbach, Ulrich ; Schelbert, Heinrich R. ; Just, Hanjoerg. / Myocardial viability in patients with ischemic cardiomyopathy - Evaluation by 3-D integration of myocardial scintigraphic data - And coronary angiographic data. In: Molecular Imaging and Biology. 2004 ; Vol. 6, No. 3. pp. 160-171.
@article{dac059b065c7482fa716f0f8d7ac9cef,
title = "Myocardial viability in patients with ischemic cardiomyopathy - Evaluation by 3-D integration of myocardial scintigraphic data - And coronary angiographic data",
abstract = "Purpose: To determine the prevalence of viable myocardium in patients with ischemic cardiomyopathy and, to evaluate the value of three-dimensional (3-D) fusion imaging of myocardial scintigraphic and angiographic data to assign coronary artery lesions to the corresponding viable and nonviable myocardial territory. Procedures: In 105 patients, the combination of perfusion and metabolic imaging with 201thallium (201TI) single-photon emission computed tomography (SPECT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) determined viability in dysfunctional myocardium. In addition, the value of 3-D scintigraphic fusion imaging was assessed in these patients. Results: Based on the presence of viable dysfunctional myocardium, 54{\%} of patients with ischemic cardiomyopathy may be considered for coronary revascularization. In 31 of 105 patients, the 3-D fusion imaging was estimated to be helpful in the diagnostic and interpretative process. Conclusion: In patients with end-stage coronary artery disease scintigraphic imaging is most important in the decision-making process. Three-dimensional fusion imaging may add important information in approximately 30{\%} of these patients.",
keywords = "3-D fusion imaging, Angiography, Cardiomyopathy, Coronary disease, Tomography, Viability",
author = "Schindler, {Thomas H.} and Nitzsche, {Egbert U.} and Nobuhisa Magosaki and Michael Mix and Facta, {Alvaro D.} and Prior, {John O.} and Ulrich Solzbach and Schelbert, {Heinrich R.} and Hanjoerg Just",
year = "2004",
month = "5",
doi = "10.1016/j.mibio.2004.02.002",
language = "English (US)",
volume = "6",
pages = "160--171",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Myocardial viability in patients with ischemic cardiomyopathy - Evaluation by 3-D integration of myocardial scintigraphic data - And coronary angiographic data

AU - Schindler, Thomas H.

AU - Nitzsche, Egbert U.

AU - Magosaki, Nobuhisa

AU - Mix, Michael

AU - Facta, Alvaro D.

AU - Prior, John O.

AU - Solzbach, Ulrich

AU - Schelbert, Heinrich R.

AU - Just, Hanjoerg

PY - 2004/5

Y1 - 2004/5

N2 - Purpose: To determine the prevalence of viable myocardium in patients with ischemic cardiomyopathy and, to evaluate the value of three-dimensional (3-D) fusion imaging of myocardial scintigraphic and angiographic data to assign coronary artery lesions to the corresponding viable and nonviable myocardial territory. Procedures: In 105 patients, the combination of perfusion and metabolic imaging with 201thallium (201TI) single-photon emission computed tomography (SPECT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) determined viability in dysfunctional myocardium. In addition, the value of 3-D scintigraphic fusion imaging was assessed in these patients. Results: Based on the presence of viable dysfunctional myocardium, 54% of patients with ischemic cardiomyopathy may be considered for coronary revascularization. In 31 of 105 patients, the 3-D fusion imaging was estimated to be helpful in the diagnostic and interpretative process. Conclusion: In patients with end-stage coronary artery disease scintigraphic imaging is most important in the decision-making process. Three-dimensional fusion imaging may add important information in approximately 30% of these patients.

AB - Purpose: To determine the prevalence of viable myocardium in patients with ischemic cardiomyopathy and, to evaluate the value of three-dimensional (3-D) fusion imaging of myocardial scintigraphic and angiographic data to assign coronary artery lesions to the corresponding viable and nonviable myocardial territory. Procedures: In 105 patients, the combination of perfusion and metabolic imaging with 201thallium (201TI) single-photon emission computed tomography (SPECT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) determined viability in dysfunctional myocardium. In addition, the value of 3-D scintigraphic fusion imaging was assessed in these patients. Results: Based on the presence of viable dysfunctional myocardium, 54% of patients with ischemic cardiomyopathy may be considered for coronary revascularization. In 31 of 105 patients, the 3-D fusion imaging was estimated to be helpful in the diagnostic and interpretative process. Conclusion: In patients with end-stage coronary artery disease scintigraphic imaging is most important in the decision-making process. Three-dimensional fusion imaging may add important information in approximately 30% of these patients.

KW - 3-D fusion imaging

KW - Angiography

KW - Cardiomyopathy

KW - Coronary disease

KW - Tomography

KW - Viability

UR - http://www.scopus.com/inward/record.url?scp=2942639845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942639845&partnerID=8YFLogxK

U2 - 10.1016/j.mibio.2004.02.002

DO - 10.1016/j.mibio.2004.02.002

M3 - Article

VL - 6

SP - 160

EP - 171

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 3

ER -